SCHEMBL2945848

SCHEMBL2945848

CCOC(=O)c1cc2cc(C(=O)O)ncc2n1Cc1ccc(F)cc1F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
MAPT P10636 10/20 0.43
POLB P06746 2/20 0.43
HTT P42858 1/20 0.43
PTGER1 P34995 3/20 0.43
TDP1 Q9NUW8 5/20 0.42
KDM4E B2RXH2 4/20 0.41
TSHR P16473 2/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NOD2 Q9HC29 2/20 0.41
NOD1 Q9Y239 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950130 0.89 MAPT (0.43) ALDH1A1MAPTPOLBHTTTDP1
SCHEMBL2943282 0.86 MAPT (0.42) ALDH1A1MAPTPOLBHTTTDP1
SCHEMBL2948573 0.81 CCR2 (0.45) ALDH1A1PTGER1KDM4EHSD17B10PTGDR2
SCHEMBL2945150 0.78 PPARG (0.47) ALDH1A1TDP1TSHR
SCHEMBL6018633 0.77 NOD2 (0.45) ALDH1A1MAPTPOLBHTTTDP1
SCHEMBL2944416 0.76 HDAC1 (0.40) ALDH1A1MAPTPTGER1TDP1PTGDR2
SCHEMBL2945336 0.74 PPARG (0.52) PTGER1
SCHEMBL3023675 0.74 NOD2 (0.43) ALDH1A1MAPTPOLBHTTTDP1
SCHEMBL3622091 0.73 NOD2 (0.47) ALDH1A1MAPTPOLBHTTTDP1
SCHEMBL2816895 0.73 F10 (0.51) ALDH1A1MAPTPOLBHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558611-B1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER (US) 2010-01-06 EP disclosed
US-20080221154-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER INC 2008-09-11 US disclosed
US-7368571-B2 HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use PFIZER INC (US) 2008-05-06 US disclosed
US-20070004768-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE AGOURON PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-7135482-B2 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-11-14 US disclosed
EP-1558611-A2 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER INC. (US) 2005-08-03 EP disclosed
US-20040147547-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-07-29 US disclosed
WO-2004039803-A2 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER INC. (US) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147547-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use IMPDH1, POLA1, POLB ALDH1A1 794/4885MAPT 2334/4885POLB 3/4885
US-20070004768-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE TYMP, IMPDH1, POLB ALDH1A1 1133/4885MAPT 2278/4885POLB 3/4885
US-20080221154-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE TYMP, IMPDH1, POLB ALDH1A1 1208/4885MAPT 1998/4885POLB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.